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Background: Pathologic complete response (pCR) is an impor-
tant predictor of long term survival in patients with breast cancer
receiving neoadjuvant chemotherapy.
Methods: Unidimensional and volumetric ultrasound mea-
surements prior to, after 4 cycles (mid-treatment), and at the
end of 8 cycles (end-treatment) of chemotherapy were available
from a subset of 55 patients enrolled in Neo-tAnGo, a phase III
neoadjuvant chemotherapy trial. Changes in proportional lon-
gest diameter (LD) and volume as well as absolute residual size
thresholds were examined for their ability to predict pCR or
pCR plus minimal residual disease (pCR/MRD). Sensitivity, spec-
ificity, positive (PPV) and negative predictive values (NPV) and
likelihood ratios (LRs) were calculated. Receiver–operator char-
acteristic (ROC) curves and logistic regression models were
constructed.
Results: At mid-treatment, neither complete radiological
response, nor proportional LD or volume changes were found pre-
dictive of final pCR. Residual tumour volume 61 cm3 was associ-
ated with pCR/MRD (p = 0.014). Sensitivity, specificity, PPV, NPV,
LR+ and LR– values were 61%, 77%, 61%, 77%, 2.62 and 0.51 respec-
tively. The area under the ROC curve (AUC) was 0.689 (p = 0.03).
Volume 61 cm3 was found significant in a univariate logistic
regression (p = 0.011), but not in multivariate analysis. At end-
treatment, no ultrasound measurements were found predictive
of pCR or pCR/MRD.
Conclusions: Proportional tumour size changes were not found
predictive of good pathologic response, yet residual volume
61 cm3 after 4 cycles of chemotherapy was found predictive. Mul-
tiple volume and LD thresholds were examined and uncorrected
p-values presented, increasing the possibility of type I errors. Rep-
lication in an independent dataset is required.
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Objective: D-dimer, the end product of coagulation, is increased
pre-operatively in abdominal cancers with poor prognosis, and in
early breast cancer is associated with lymph node positivity. How-
ever, d-dimer as a marker of response to treatment has not been
investigated.
Methods: In early breast cancer patients receiving neoadjuvant
chemotherapy (n = 11), d-dimer was measured prior to com-
mencement of chemotherapy and at 6 months following com-
mencement of treatment. Clinical and radiological follow-up of
breast cancer was at 3, 6, 12 and 24 months. We compared base-
line d-dimer, d-dimer at 6 months, and change in d-dimer in
response to treatment in patient with relapse compared to those
remaining disease free at 2 years.
Results:
Relapse at
2 years
Disease free at
2 years
P-value
D-dimer pre-
chemotherapy,
ng/ml (SD) (n)
1328 (1183) (3) 259 (91) (7) 0.03
D-dimer at
6 months,
ng/ml (SD) (n)
1364 (221) (2) 454 (224) (5) 0.005
Change in
d-dimer in
response to
chemotherapy,
ng/ml (SD) (n)
717 (345) (2) 177 (188) (5) 0.04
(Upper limit of normal 500 ng/ml).
No patients had clinical evidence of relapse at 6 months.
Conclusions: Despite no clinical evidence of disease, d-dimer
remains elevated at 6 months following breast cancer treatment
in patients with early relapse. D-dimer, prior to treatment and fol-
lowing treatment, may act as a marker for early relapse in breast
cancer.
doi:10.1016/j.ejcsup.2010.06.033
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Introduction: Development of gene signatures usually focuses on
changing timedependent data into binary categories, for example 5
year survival. Predicting actual time to an event has thepotential to
be much more powerful. Here we introduce a novel algorithm
termedRiskDistiller that aims toovercome the splitting of data into
arbitrary categories by using artificial neural networks to predict a
continuous response variable describing the actual time to event.
Methods: Time to recurrence data (0–14 years) for a series of
breast cancer patients was made available in a study described
by Van de Vijver et al. We applied our method to those cases with
known events to identify an optimal panel of genes with the abil-
ity to predict the actual time to recurrence. The gene signature
started as a single gene and was grown upwards until the optimal
model was determined.
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